Author Archives: Scalper1

Firearms Stocks: On Track For Gains Or A Pullback?

Sometimes a niche product within an industry group can call for separate attention. That is probably the case with the three small arms weapons makers in the Security/Safety industry group. The other companies don’t deal in firearms. The security group is down about 11% so far this year vs. a 9% loss in the S&P 500 and a 13% decline in the Nasdaq. However, Sturm Ruger ( RGR ) is up 6% and Smith & Wesson ( SWHC ) is almost flat. Electrical weapons maker Taser ( TASR ) is down 9% year to date. Let’s look at the three stocks. Sturm Ruger has a Composite Rating of 91, putting it in the top 9 percentile of the stocks in IBD’s database. The Street expects full-year 2015 earnings growth to come in at 58% when the company reports later this month. Revenue is expected to slip 1.6%. For 2016, analysts expect earnings to grow 19% on a revenue gain of about 9%. Quarterly after-tax margin dropped to 9.9% in the third quarter. The median after-tax margin since mid-2011 is about 14%. Ruger’s chart shows that its last good breakout was in September 2013, which led to a gain of about 40%. More recent breakouts didn’t yield much. The best was a 12% gain out of a breakout from a flat base in July. The stock has retaken its 50-day and 200-day lines and is about 6% off its high. Smith & Wesson has a Composite Rating of 98. In fiscal 2016 ending in April, the Street expects the company to grow earnings 40% on a 19% sales gain, but the following year only 10% EPS growth on 6% revenue growth. Like Ruger, after-tax margin was 9.9% in its most recent quarter. Smith & Wesson’s margins vary quite a bit — from as high as 26% to as little as 2.5%. Smith & Wesson’s chart shows that the stock has spent most of its time since 2002 trading below 15 a share. This raises concerns that the strength in firearms sales is baked into the price, leaving the stock vulnerable to a pullback. Management has expressed an interest in making an acquisition in the outdoor sporting goods area. While that might sound like a good marriage, Smith & Wesson has a spotty history in acquisitions. The company admitted in its 2014 10-k report that, “We have limited acquisition experience.” The acquisition of Thompson Center Arms in January 2007 and Universal Safety Response in July 2009 led to substantial write-downs. Taser International is in sad shape chartwise. The stock is 56% off a high dating to June. The Street expects a 16% drop in full-year 2015 EPS when the company reports later this month. Revenue is expected to grow 17%. After-tax margin dropped to 3% in Q3. Taser’s chart shows plenty of good gains in its history, but the current consolidation is deep and ugly.  

Mylan Will Buy Meda For $9.9 Billion, Q4 Earnings Miss; Stock Dives

Generic-drug giant Mylan ( MYL ) announced a $9.9 billion buyout of Swedish counterpart Meda late Wednesday, as it also reported Q4 earnings that missed estimates. The stock tumbled in after-hours trading. Mylan said that the acquisition will be immediately accretive to earnings, adding 35 to 40 cents to EPS next year. That will allow the company to hit its previously stated target of $6.00 a share to earnings a year earlier than the expected 2018. The deal will hike Mylan’s annual revenue by about 25%, and bring $350 million in annual cost savings, Mylan said. Mylan is offering a mixture of cash and stock that adds up to 165 Swedish kronor per Meda share, which including Meda’s net debt adds up to $9.9 billion. “This transaction builds on everything we have put in place around the world, including our recent acquisition of the Abbott ( ABT ) non-U.S. developed markets specialty and branded generics business,” Mylan CEO Heather Bresch said in a statement. “Meda brings us greater scale, breadth and diversity across products, geographies and sales channels, and together we will have an even stronger global commercial infrastructure.” Mylan also said that its Q4 earnings totaled $1.22 a share, up 16% from the year-earlier quarter but 6 cents below analysts’ consensus, according to Thomson Reuters. Revenue climbed 20% to $2.49 billion, more than $200 million short of consensus. For the full 2015, EPS rose 21% to $4.30 while revenue gained 28% to $9.45 billion. Mylan also offered 2016 guidance that assumes that the Meda deal will close at the end of Q3, with $10.5 billion to $11.5 billion in sales and $4.85 to $5.15 in EPS. Analysts did not include Meda in their consensus of $5.00 in EPS and $10.6 billion in sales, but Bresch said the firm is “committed to our 2016 guidance ranges with or without Meda.” Mylan stock, which holds a strong Composite Rating of 89, fell 0.4% in regular trading on the stock market today to close at 50.54. Mylan lost 9% to 45.85 after hours.